Application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma

An immunoregulatory protein, glioma technology, applied in the field of biomedicine, can solve problems such as unreported, and achieve significant effects

Inactive Publication Date: 2014-09-17
张喜田 +1
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ganoderma lucidum immunoregulatory protein (LZ-8), one of the active ingredients in Ganoderma lucidum, is a fungal immunoregulatory protein extracted from red Ganoderma lucidum. The recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) provided in this paper is a new Design and fully synthesize the LZ-8 gene, and use the Pichia pastoris expression system to express and purify the obtained protein samples. Previous studies have shown that rLZ-8 also has certain anti-tumor activity. For example, rLZ-8 can effectively kill human Lung adenocarcinoma tumor cells (A549), human gastric adenocarcinoma cells (SGC7901) and other tumor cell lines, but there is no report on the therapeutic effect of rLZ-8 on lung cancer, laryngeal cancer and brain glioma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma
  • Application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma
  • Application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1 Effect of rLZ-8 on the tumor suppression rate and tumor-bearing survival rate of lung metastatic mice (LLC)

[0016] 1 drug preparation

[0017] The concentration of the rLZ-8 protein stock solution was 1 mg / ml, respectively configured into rLZ-8 low dose (250 μg / kg) 31.25 μg / ml solution, rLZ-8 medium dose (500 μg / kg) 62.5 μg / ml solution, rLZ-8 8 high dose (1000μg / kg) 125μg / ml solution.

[0018] Establishment of a mouse model of lung cancer

[0019] Collect LLC cells in the logarithmic growth phase, centrifuge at 1000r / min for 5min, remove the supernatant, suspend the cells in saline solution, and adjust the cell concentration to 8.5×10 6 / ml. Take the cell suspension tail vein and inoculate it in mice, the number of inoculated cells is 1.7×10 6 each, the inoculation volume is 0.2ml / only.

[0020] Experimental grouping and administration method

[0021] 126 healthy and flexible C57BL / 6 mice were randomly divided into 7 groups, 18 mice in each grou...

Embodiment 4

[0037] Example 4: Effect of rLZ-8 on tumor morphology and tumor inhibition rate of nude mouse laryngeal carcinoma model and nude mouse glioma model

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of recombinant ganoderma lucidum immunomodulatory protein rLZ-8 in treating lung cancer, laryngocarcinoma and brain glioma. According to the invention, the in-vivo anti-tumor effect of the rLZ-8 is researched by respectively building a lung cancer mice model by virtue of a caudal vein injection method and building a laryngocarcinoma and brain glioma nude mice animal model by virtue of a subcutaneous transplantation tumor method; a treatment result indicates that the rLZ-8 achieves an obvious anti-tumor effect on the lung cancer, the laryngocarcinoma and the brain glioma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to the application of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) in the preparation of anti-tumor drugs, and focuses on the application of recombinant Ganoderma lucidum immune regulatory protein (rLZ-8) in resisting lung cancer, laryngeal cancer and brain glial The therapeutic effect of tumor growth, improve the living conditions of tumor-bearing mice and improve the survival rate of tumor-bearing mice. . Background technique [0002] Lung cancer is a malignant tumor derived from epithelial cells of the bronchi or bronchioles, accounting for 90-95% of lung parenchymal malignant tumors. Lung cancer is the most common primary malignant tumor of the lung. According to the survey report of the World Health Organization, in many countries and regions, the incidence of lung cancer accounts for the first place among malignant tumors. The disease mostly occurs in people over ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P35/00
CPCA61K38/16
Inventor 孙非梁重阳张喜田
Owner 张喜田
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap